Background: CD5-positive (CD5+) diffuse large B-cell lymphoma (DLBCL) shows poor prognosis and frequent central nervous system (CNS) relapses under anthracycline-containing chemotherapy. The aim of this study was to determine the prognosis and CNS relapse incidence of CD5+ DLBCL in the rituximab era.
introduction Diffuse large B-cell lymphoma (DLBCL) is the largest lymphoma subcategory and has heterogeneous biological properties [1] . DLBCL cases (5%-10%) are CD5 positive (CD5+) [2] [3] [4] [5] . CD5+ DLBCL has been included as an immunohistochemical subgroup in the fourth edition of the World Health Organization (WHO) classification [1] . Our two nationwide retrospective studies in Japan [6, 7] revealed that CD5+ DLBCL was associated with female predominance, higher age at diagnosis, higher serum lactate dehydrogenase (LDH) level, and higher risk groups in the international prognostic index (IPI) [8] . In the pre-rituximab era, CD5+ DLBCL showed a significantly poorer survival outcome than CD5-negative DLBCL under conventional anthracyclinecontaining chemotherapy [6, 9, 10] . CD5+ DLBCL is also characterized by a high central nervous system (CNS) relapse rate [7] .
The current standard therapy for DLBCL incorporates rituximab, but three independent groups have reported that CD5+ DLBCL is associated with a poorer overall survival (OS) rate than CD5-negative DLBCL, regardless of the use of rituximab [3, 10, 11] . To explore a more effective therapeutic strategy for CD5+ DLBCL, it is important to examine the response and failure rate of chemotherapy with rituximab in a large number of CD5+ DLBCL cases.
Hence, we conducted the third nationwide retrospective study of >300 Japanese patients with CD5+ DLBCL who received chemotherapy with (R-chemotherapy group) or without (chemotherapy group) rituximab.
patients and methods

patients and treatment
Two hundred and eighty-one patients who were diagnosed with CD5+ DLBCL between 2002 and 2007 were retrospectively registered in this study from 31 participating centers. CD5+ DLBCL was diagnosed by expert hematopathologists (listed in the Appendix) in accordance with the WHO classification [1] . CD20 and/or CD79a positivity on the tumor cells was confirmed by immunohistochemical staining or flow cytometry. Based on our experience that CD5 expression in DLBCL was less visible when tissue sections were examined using paraffinized materials [7] , we primarily used flow cytometry and/or immunohistochemical analysis of frozen sections to examine the expression of CD5. We used paraffin-embedded sections only if fresh or frozen material was unavailable. We registered consecutive patients who were diagnosed with CD5+ DLBCL, regardless of the availability of follow-up data. Intravascular large B-cell lymphoma [12] , primary DLBCL of the CNS, secondary CD5+ DLBCL [4] , cyclin D1+ cases, and cases with insufficient follow-up data were excluded from the study population ( Figure 1) . Patients who had not received any chemotherapy were also excluded. As a result, 230 patients were included in the present series ( Figure 1 ). The study protocols used were approved by the institutional review board at each participating hospital and complied with all provisions of the Declaration of Helsinki.
We previously reported an analysis of 120 patients with CD5+ DLBCL from a pathological perspective [7] . Our current cohort also included 107 of these 120 patients from our previous series. The remaining 13 patients were excluded as they had not received chemotherapy. The final total of the patient cohort in the present analysis was thus 337 patients with CD5+ DLBCL who had received chemotherapy (Figure 1 ). In 95 of these patients (28%), CD5 expression could only be examined by immunohistochemistry using paraffin sections.
Patients received treatment for CD5+ DLBCL according to the respective institutional protocols. Patients who had received any rituximab treatment cycles (median, seven cycles; range one to eight cycles) were assigned to the R-chemotherapy group, and the dose of rituximab was 375 mg/m 2 for all patients in this group. A pretreatment evaluation of the cerebrospinal fluid (CSF) was not required. CNS prophylaxis was carried out on a patient-bypatient basis in accordance with the clinical decisions made within each institute.
definition of CNS relapse
The definition of CNS relapse used in the current study was previously reported by Bernstein et al. [13] 
results
patient characteristics
Patient characteristics are listed in Table 1 . The chemotherapy group composed of 153 patients, whereas the R-chemotherapy group contained 184 patients ( Figure 1 ). The median age of all patients in both groups was 65 and 67 years, respectively. In the R-chemotherapy group, 103 patients (60%) were older than 65 years. No statistically significant differences in baseline patient characteristics were found between the two groups.
treatments Treatment details are summarized in Table 2 . A total of 147 patients (97%) in the chemotherapy group and 180 patients (98%) in the R-chemotherapy group received anthracyclinecontaining chemotherapy. The most popular chemotherapeutic regimen was a standard CHOP (combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone) (-like) regimen, which was selected as an initial treatment for 111 patients (73%) in the chemotherapy group and for 168 patients (91%) in the R-chemotherapy group. In the chemotherapy group, 24% of the patients received chemotherapies that were more intensive than the standard CHOP (-like) regimen. CNS prophylaxis was carried out in five patients in the chemotherapy group. Among them, four patients received intrathecal administration of methotrexate and the remaining Figure 1 . Patient selection. *Forty-three patients were excluded due to the following reasons: lack of clinical data (n = 25), intravascular large B-cell lymphoma (n = 2), primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (n = 7), secondary CD5-positive DLBCL (n = 6), cyclin D1+ cases (n = 2), and non-DLBCL status (n = 1).
original article Annals of Oncology patient received whole-brain radiation. CNS prophylactic therapy was conducted more frequently in the R-chemotherapy group than in the chemotherapy group (P < 0.001; Table 2 ). Of these individuals, 25 patients received an intrathecal administration of methotrexate with or without cytarabine. Two patients received whole-brain radiotherapy because they had CNS involvement as well as systemic involvement at diagnosis.
Five patients (3%) in the chemotherapy group and 21 patients (11%) in the R-chemotherapy underwent stem-cell transplantation (SCT), with two of these patients in the Rchemotherapy group receiving allogeneic SCT.
response to initial therapy and survival CR was achieved after initial treatment in 101 (66%) patients in the chemotherapy group and 148 (80%) patients in the R-chemotherapy group. The CR rate was significantly higher in the R-chemotherapy group (P = 0.003). The median follow-up of surviving patients was 68 months (range 6-190 months) in the chemotherapy group and 30 months (range 7-82 months) in the R-chemotherapy group. The OS in the R-chemotherapy group was also significantly higher than that in the chemotherapy group (log-rank test, P = 0.002; Figure 2 ). The 2-year OS rate was 54% in the chemotherapy group and 70% in the R-chemotherapy group.
The results of our univariate and multivariate analyses of the OS rates to assess the impact of clinical features in the entire cohort of 337 CD5
+ DLBCL patients are shown in Table 3 . By univariate analysis, we identified chemotherapy without rituximab, male sex, the presence of B symptoms, and all five risk factors of the IPI as important prognostic factors for the OS. Intensive chemotherapy was not associated with a reduced OS. By multivariate analysis, chemotherapy without rituximab [hazard ratio (HR) 1.72; 95% confidence interval (CI) 1.23-2.43; P = 0.002], male sex, and all the risk factors of the IPI except for extranodal sites were each identified as independent prognostic factors affecting the OS. In addition, when multivariate analysis was carried out for chemotherapy without rituximab, male sex and all IPI categories were found to be significant and independent prognostic factors. In the R-chemotherapy group, 19 patients received autologous SCT. Among them, all eight patients who received autologous SCT during the first CR had survived without relapse as of the last follow-up (median progression-free survival of 43 months).
CNS relapse in CD5+ DLBCL
Among our 337 patient subjects, 25 in the chemotherapy group and 24 in the R-chemotherapy group experienced CNS relapse during the follow-up period (Table 2 ). There was no significant difference in the probability of CNS relapse between these two groups (P = 0.89, Figure 3A) . The 2-year CNS relapse rate was found to be 11.6% (95% CI 7.1% to 18.6%) in the chemotherapy group and 12.7% (95% CI 8.5% to 18.8%) in the R-chemotherapy group. A time-dependent covariate analysis of the R-chemotherapy group further revealed that CNS relapse strongly affected the OS of CD5+ DLBCL (P < 0.0001, Figure 3B) .
Twenty of 24 patients in the R-chemotherapy group and 19 of 25 patients in the chemotherapy group experienced an isolated CNS relapse. Patterns of CNS relapse in both groups are shown in Table 2 . In both groups, brain parenchymal relapse was the most frequent pattern of CNS relapse (60% in the chemotherapy group and 66% in the R-chemotherapy group). The incidence of each pattern of CNS relapse did not significantly differ between these two groups. In the R-chemotherapy group, 83% (20/24) of patients who experienced CNS relapse had parenchymal disease.
To identify risk factors of CNS relapse in CD5+ DLBCL, we carried out univariate analyses of all the risk factors that had been analyzed in the largest cohort of DLBCL in the report from Boehme et al. [14] . Advanced stage, poor performance status, high serum LDH level, the presence of B symptoms, and bone marrow and/or peripheral blood involvement were found to be significant risk factors by univariate analyses (supplemental Table S1 , available at Annals of Oncology online). The multivariate analysis showed that poor performance status was the only independent risk factor for 2-year CNS relapse (HR 2.81, 95% CI 1.54-5.13; P = 0.001). Among the 24 patients who experienced CNS relapse in the R-chemotherapy group, 11 patients (46%) had bone marrow involvement at diagnosis. In addition, seven patients (29%) received CNS prophylaxis during first-line therapy. Of those patients, five received an intrathecal administration of methotrexate with or without cytarabine original article Annals of Oncology and one received whole-brain radiotherapy. For the remaining patient, there was no available data concerning CNS prophylaxis.
discussion
Our current retrospective study confirms that the OS of CD5+ DLBCL is improved by addition of rituximab to conventional chemotherapies. We also demonstrate that the 2-year CNS relapse rate in CD5+ DLBCL remains high (12.7%) despite the use of rituximab and that CNS relapse is significantly associated with shortened survival of these patients. We previously reported a high CNS relapse rate (13%) in 120 patients with CD5+ DLBCL at a median follow-up of 6.8 years [7] . The incidence of CNS relapse in aggressive non-Hodgkin's lymphomas, except in lymphoblastic lymphoma and Burkitt's lymphoma, has been reported to be £5% [15] [16] [17] . In the present study, the 2-year CNS relapse rate of CD5+ DLBCL was 11.6% in the chemotherapy group and 12.7% in the R-chemotherapy group. These two rates were not significantly different, which indicates not only that CD5+ DLBCL has a high CNS relapse rate but also that the addition of rituximab did not reduce the CNS relapse rate in patients with CD5+ DLBCL. Although the observation period in the Rchemotherapy group was shorter than that of our previous study (30 versus 81 months), the incidence of CNS relapse was still >30%. Moreover, our results show that CNS relapse affected the reduced OS rate of CD5+ DLBCL in the R-chemotherapy group. These findings suggest that CNS prophylaxis is required to further improve the OS of CD5+ DLBCL in the rituximab era.
A large retrospective study from Germany identified risk factors for CNS relapse in elderly patients with DLBCL [14] . The presence of more than one site of extranodal involvement and B symptoms were identified as independent risk factors for CNS relapse by multivariate analysis. In contrast, poor performance status was the only independent risk factor for 2-year CNS relapse in our CD5+ DLBCL cohort. We considered that this discrepancy in the results between the German study and ours may be due to difference in the disease status of the subjects analyzed; our cohort was composed of CD5+ DLBCL patients only and, therefore, not representative of all types of DLBCL. In primary DLBCL of the CNS, the most common site of involvement is the brain parenchyma [1] . Chemotherapy with high-dose methotrexate followed by whole-brain radiotherapy is the most commonly used approach for this disease [18] . As 75% of patients who experienced CNS relapse had brain parenchymal disease (18 of 24) in the current study of CD5+ DLBCL, high-dose methotrexate may be more efficacious than intrathecal administration of methotrexate or cytarabine to prevent CNS relapse in CD5+ DLBCL patients. High-dose chemotherapy with autologous SCT also appears to be an effective approach in patients with CD5+ DLBCL because some clinical trials have indicated efficacy for CNS lymphoma [19, 20] . However, it should be noted that 60% of our patients with CD5+ DLBCL were older than 65 years at diagnosis and would therefore not be eligible for high-dose chemotherapy.
Several clinical parameters such as elevated serum LDH levels and extranodal or bone marrow involvement have been established as risk factors for CNS relapse in DLBCL [13, 21, 22] . Based on the recent results of a study of aggressive lymphoma, which mainly comprises DLBCL [13] , bone marrow involvement seems to be less significant. To date, CD5 antigen expression is the only well-known molecular marker that is closely associated with frequent CNS relapse in DLBCL. Quijano et al. [23] developed a sensitive immunophenotyping method for lymphoma cells in the CSF that turned out to be useful in detecting unexplained CNS involvement upon the diagnosis of DLBCL. To investigate the significance of CD5 expression in CNS relapse of DLBCL, further studies using such a procedure may be useful. The relationship between CD5+ DLBCL and primary DLBCL of the CNS should be clarified because the latter frequently shows expression of CD5 (30%) [24] . Such approaches would be expected to contribute to the establishment of both early diagnosis of CNS involvement and optimal treatment in CD5+ DLBCL patients.
In conclusion, we herein report detailed therapeutic and prognostic results for a fairly large number of CD5+ DLBCL cases. Despite the use of rituximab, the 2-year OS of CD5+ DLBCL remains poor (70%). As CD5+ DLBCL is complicated by a high incidence of CNS relapse, a more effective therapeutic strategy with CNS prophylaxis is needed.
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